Good afternoon Vancouver 🌞🏔️ It’s 2026 and melanoma data continue to move in TIL 🏋️♀️
@drbetofmdphd.bsky.social discusses 10 year melanoma survival data for patients who have experienced complete response with earlier versions of TIL #MovingTheGoalPosts #CMC26 @stanford-cancer.bsky.social
Stanford #Melanoma’s @funchainmd.bsky.social leading us through a fantastic discussion of immune checkpoint toxicity #irAE in patients with pre-existing autoimmune disease. #CMC26 @stanforduniversity.bsky.social
An entire day for solid tumor at #iwCART25! How far we’ve come in solid tumor cell therapy- 2 approvals since I was at this meeting last year! Looking forward to a great meeting.
New Journal for ImmunoTherapy of Cancer (JITC) commentary: Role of high-dose interleukin-2 for melanoma in the age of cellular therapy bit.ly/4jwhLmm
@drbetofmdphd.bsky.social #JITC #research #cancer 🧪
Melanoma rapid oral #9 ➡️ OBX-115, engineered TIL with membrane bound IL15 regulated with acetazolamide
-for 6pt receiving RP2D, 67% ORR, 1 CR, 100% DCR
-mDOR not reached
Jason Chesney U Louisville and @drbetofmdphd.bsky.social @stanford-cancer.bsky.social
#ASCO25 @ascocancer.bsky.social
Pushing through boundaries in solid tumor cell therapy @stanford-cancer.bsky.social 📈
➡️ only 1 of 10 centers that offers sarcoma TCR-T
➡️ 50% DCR with TIL in melanoma brain mets and promising safety signal, no seizures or hemorrhages 🤞🙏 @drbetofmdphd.bsky.social @stevenartandi.bsky.social
Fantastic panel moderated by @drbetofmdphd.bsky.social - so many melanoma trials open/opening in the Bay Area. Great company, great colleagues, and great movement to make melanoma outcomes better here in the Bay Area, and everywhere 🖤 Thanks to ANCO for continuing to elevate oncology in NoCal ⛰️
Following FDA approval of lifileucel for advanced melanoma in early 2024, U.S. centers have been learning how to best deliver this novel “living” drug. For #ASCODailyNews, @maxjulve.bsky.social & @drbetofmdphd.bsky.social discuss the real-world challenges facing clinicians: https://bit.ly/48nBPor
Allison Betof Warner, MD, PhD
Pauline Funchain
Enjoyed discussing LAG3 targeting #melanoma w
@drbetofmdphd.bsky.social Major role for relatlimab while fianlimab data look as good/better so far! Field has been waiting long time for RELA-098 but Ph3 studies abound for cemi-fian metastatic, adjuvant and peri-op!
www.medscape.org/viewarticle/...
Allison Betof Warner, MD, PhD
The #OncoAlertColloquium 2026 Thoracic Malignancies🚨 DAY FIVE
Presentation by Dr. Gilberto Lopes🇺🇸 : Year in Review Early #NSCLC
REGISTER HERE TO WATCH: buff.ly/xwD5G2D
Practice-changing research in 2025 in early NSCLC 🚀
